Medicine
Promacta 50 mg tablet
Promacta 50 mg tablet is a prescription medicine containing Eltrombopag for oral use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature between 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Eltrombopag
- Brand
- Promacta
- Strength
- 50 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 14 tablets
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at room temperature between 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Each kit (NDC 0078-0697-61) contains 30 packets: NDC 0078-0697-19 Store at room temperature between 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B02BX05 Eltrombopag
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 April 2016
- Identifiers
- RxCUI 825421, 825425, 825427 +7DailyMed set ID 7714a0ed-34bb-46e6-a0a5-b363908b22c2NDC 0078-0686Application NDA022291
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 0078-0686-15 | Novartis Pharmaceuticals | 7 April 2016 |
| 14 tablet, film coated in 1 bottle | 0078-0686-55 | Novartis Pharmaceuticals | 21 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Eltrombopag 50 mg tablet.
Other strengths and forms of Eltrombopag
Clinical summary
Eltrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids. MedsAcross supplies Eltrombopag for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EltrombopagFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- PROMACTA prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Revolade: European public assessment report (EPAR) · European Medicines Agency
- Eltrombopag Accord: European public assessment report (EPAR) · European Medicines Agency
Need Promacta 50 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.